Stephen Kaldor, PhD

Steve is a Venture Partner with Versant Ventures and is also the CEO of Quanticel Pharmaceuticals, a privately held Versant portfolio company focused on cancer drug discovery.

Steve was CEO of Ambrx from 2007-2010 and helped this biologics company mature its drug portfolio and platform through deals with Pfizer, Merck, Lilly, and Merck-Serono.

Steve served as President & CSO of Syrrx from 2002-2005, and led the company through its $270M acquisition by Takeda in 2005 and for several years post acquisition. Prior to joining Syrrx, Steve gained 12 years of R&D experience at Eli Lilly as both a researcher and Director.

A chemist by training, Steve is a co-inventor of ten therapeutic compounds that have entered the clinic including Viracept, a marketed AIDS medication, and Nesina, a marketed diabetes medication.

Steve also serves as an independent board member for various companies including Furiex (2010 – current), Amira (2008 through 2011 acquisition by BMS) and Anaphore (2008 – 2011). He received a PhD from Harvard University and a BA from Columbia University.

Sarah Cross